Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease
How will computational and AI tools guide future anticancer strategies?
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Hortobagyi: “Patient involvement is central to advance research in breast cancer”
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials